 Drug-Related Side Effects and Adverse Reactions
"Drug-Related Side Effects and Adverse Reactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Descriptor ID |
D064420
|
| MeSH Number(s) |
C25.100
|
| Concept/Terms |
Drug-Related Side Effects and Adverse Reactions- Drug-Related Side Effects and Adverse Reactions
- Drug Related Side Effects and Adverse Reactions
- Side Effects of Drugs
- Drug Side Effects
- Drug Side Effect
- Effects, Drug Side
- Side Effect, Drug
- Side Effects, Drug
- Adverse Drug Reaction
- Adverse Drug Reactions
- Drug Reaction, Adverse
- Drug Reactions, Adverse
- Reactions, Adverse Drug
- Adverse Drug Event
- Adverse Drug Events
- Drug Event, Adverse
- Drug Events, Adverse
Drug Toxicity- Drug Toxicity
- Toxicity, Drug
- Drug Toxicities
- Toxicities, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug-Related Side Effects and Adverse Reactions".
Below are MeSH descriptors whose meaning is more specific than "Drug-Related Side Effects and Adverse Reactions".
This graph shows the total number of publications written about "Drug-Related Side Effects and Adverse Reactions" by people in this website by year, and whether "Drug-Related Side Effects and Adverse Reactions" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 1 | 1 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 0 | 1 | 1 | | 2001 | 3 | 1 | 4 | | 2002 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 2 | 0 | 2 | | 2006 | 3 | 3 | 6 | | 2007 | 1 | 4 | 5 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 3 | 3 | | 2010 | 1 | 2 | 3 | | 2011 | 5 | 3 | 8 | | 2012 | 3 | 5 | 8 | | 2013 | 6 | 8 | 14 | | 2014 | 3 | 5 | 8 | | 2015 | 10 | 4 | 14 | | 2016 | 5 | 5 | 10 | | 2017 | 6 | 8 | 14 | | 2018 | 2 | 2 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug-Related Side Effects and Adverse Reactions" by people in Profiles.
-
Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingel U, Büchel C, Carvalho C, Colagiuri B, Crum AJ, Enck P, Gaab J, Geers AL, Howick J, Jensen KB, Kirsch I, Meissner K, Napadow V, Peerdeman KJ, Raz A, Rief W, Vase L, Wager TD, Wampold BE, Weimer K, Wiech K, Kaptchuk TJ, Klinger R, Kelley JM. Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus. Psychother Psychosom. 2018; 87(4):204-210.
-
Camacho DM, Collins KM, Powers RK, Costello JC, Collins JJ. Next-Generation Machine Learning for Biological Networks. Cell. 2018 06 14; 173(7):1581-1592.
-
Smith MY, Russell A, Bahri P, Mol PGM, Frise S, Freeman E, Morrato EH. The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products. Drug Saf. 2018 Apr; 41(4):389-401.
-
Daniels AL, Randolph TW. Flow Microscopy Imaging Is Sensitive to Characteristics of Subvisible Particles in Peginesatide Formulations Associated With Severe Adverse Reactions. J Pharm Sci. 2018 05; 107(5):1313-1321.
-
Onysko M, Anderson HM, Cai S, Winslow BT. 5 drug interactions you don't want to miss. J Fam Pract. 2017 Nov; 66(11):680-686.
-
Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC. A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Dec 15; 23(24):7490-7497.
-
Berry SA, Longo N, Diaz GA, McCandless SE, Smith WE, Harding CO, Zori R, Ficicioglu C, Lichter-Konecki U, Robinson B, Vockley J. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2months to 2years. Mol Genet Metab. 2017 11; 122(3):46-53.
-
Ikeda K. Drug-Induced Oral Complications. Atlas Oral Maxillofac Surg Clin North Am. 2017 Sep; 25(2):127-132.
-
Farrugia LA, Rhyee SH, Calello DP, Campleman SL, Riederer AM, Malashock HR, Pizon A, Wiegand T, Wax PM, Brent J. The Toxicology Investigators Consortium Case Registry-the 2016 Experience. J Med Toxicol. 2017 Sep; 13(3):203-226.
-
Gray JE, Heist RS, Starodub AN, Camidge DR, Kio EA, Masters GA, Purcell WT, Guarino MJ, Misleh J, Schneider CJ, Schneider BJ, Ocean A, Johnson T, Gandhi L, Kalinsky K, Scheff R, Messersmith WA, Govindan SV, Maliakal PP, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM. Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I-inhibiting Antibody-Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan. Clin Cancer Res. 2017 Oct 01; 23(19):5711-5719.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|